CA-PEARL
Pearl, the global leader in dental AI, today announced that it has raised $58 million in Series B funding to accelerate its mission to elevate patient care in dentistry. Left Lane Capital led the round, with participation from Smash Capital, Alpha Partners, and existing investors, Craft Ventures and Neotribe Ventures. This funding marks the largest investment ever in dental artificial intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724200226/en/
Pearl, the global leader in dental AI, today announced that it has raised $58 million in Series B funding to accelerate its mission to elevate patient care in dentistry. (Photo: Business Wire)
With this investment, Pearl will continue to advance innovation in technologies that enhance the health of dental patients around the world by expanding its line of dental AI products, broadening its regulatory and patent portfolio, and increasing global access to the transformative benefits of AI in dentistry. At present, Pearl’s machine learning and computer vision tools solve a core challenge in dentistry: inconsistency in diagnostic accuracy, which directly impacts the quality of patient care. The company’s AI serves as a real-time aid to help dentists read patient x-rays, deliver consistent, objective, and accurate diagnoses, and clearly communicate findings to patients with precision, clarity, and confidence.
Since receiving the first-ever FDA clearance for AI software to help dental professionals detect multiple different pathologies and other conditions in x-rays, Pearl’s clinical AI has gained regulatory authorizations for chairside use in over 120 countries and recognition among TIME’s Best Inventions. The company plans to use the funding announced today both to accelerate ongoing development of computer vision capabilities – including detection and tracking of disease in 3D and other imaging modalities – and introduce new AI tools to improve patient treatment planning, insurance claim approvals and dental education.
“In the field of healthcare, dentistry has become an AI standard-bearer, demonstrating the technology’s enormous utility and benefit in day-to-day patient care––and Pearl has led the AI charge in dentistry,” said Ophir Tanz, founder and CEO of Pearl. “This historic funding round underscores the impact of Pearl’s capabilities and supports our belief that high-quality, AI-powered dental care should be accessible to everyone. With this investment, Pearl will continue to push the envelope, providing pioneering machine learning to improve oral health outcomes and strengthen trust between the patient and dental professionals.”
This investment follows a period of significant growth for Pearl. The company grew its revenue by 458% in 2023 and remains the only dental AI company with a global market presence. Pearl’s technology is used in dental practices across six continents and is commercially available to over 500,000 dental practices and millions of dental professionals worldwide. The company has also integrated its AI into dozens of popular imaging and practice management systems and is the preferred radiologic AI provider for leading dental technology distributors.
“We have spent the past year evaluating this market and it is clear that Pearl stands above peers at the forefront of dental innovation,” said Vinny Pujji, Managing Partner at Left Lane Capital. “Pearl’s pioneering dental Al improves diagnostic accuracy and efficiency while transforming the provider-patient relationship. We’re confident in Pearl’s ability to continue setting new standards of care and are thrilled to support their next phase of growth.”
Pearl’s AI technology offers a seamless and less invasive approach to dental diagnostics. By accurately detecting disease and displaying clinical findings that are easy for patients to understand, the company’s FDA-cleared software enhances the efficiency, consistency, and precision of radiologic exams, while also facilitating patient education and engagement in their dental health. Leveraging its new funding, Pearl will enable dental professionals to continually raise the standard of care with more transparent, accurate and objective diagnoses, more effective individualized care, and deeper patient trust in dentistry.
For more information on how Pearl’s suite of solutions can enhance your dental practice, visit hellopearl.com.
About Pearl
Pearl is an AI-driven company committed to enhancing patient care in dentistry. Founded in 2019 by a team with decades of experience developing successful, enterprise-grade computer vision solutions, Pearl introduced the first-ever FDA-cleared AI capable of reading and instantly identifying diseases in dental x-rays. With regulatory clearance in 120 countries, Pearl’s AI assists dentists in making precise clinical decisions and effectively communicating with patients, thereby transforming the dental care experience worldwide. As dentistry’s global AI leader, Pearl is committed to the ongoing innovation of robust, accessible AI tools that improve patient health outcomes and build greater trust in dental medicine. To request a demo, please visit hellopearl.com/getdemo.
About Left Lane Capital
Founded in 2019, Left Lane Capital is a New York and London-based global venture capital and growth equity firm investing in internet and technology companies with a consumer orientation. Left Lane’s mission is to partner with extraordinary entrepreneurs who create category-defining companies across growth sectors of the economy, including software, healthcare, e-commerce, consumer, fintech, medtech, and other industries. Select investments include Bilt Rewards, Polycam, Kings League, M1 Finance, Wayflyer, Masterworks, Blank Street, Talkiatry, LemFi, and more. For more information, please visit www.leftlane.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724200226/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom